Browsing O - Articles científics by Title

B Cells in Breast Cancer Pathology

Li, Mengyuan; Quintana Vega, Angela; Alberts, Ellie; Hung, Miu Shing; Boulat, Victoire; Martí, Mercè; Grigoriadis, Anita (MDPI, 2023-02-28)

B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

Infante, Maria Stefania; Salmanton‑García, Jon; Marchesi, Francesco; Jaksic, Ozren; Cabirta Touzon, Alba; Fernández-Cruz, Ana; Weinbergerova, Barbora (Frontiers Media, 2022-10-03)

Back-to-back discovery, co-precision, and prevention

Casadei, Barbara; Tabernero Caturla, Josep (Oxford University Press, 2020-04)

BARD1 Pathogenic Variants Are Associated with Triple-Negative Breast Cancer in a Spanish Hereditary Breast and Ovarian Cancer Cohort

Rofes, Paula; del Valle, Jesús; Torres Esquius, Sara; Feliubadaló, Lídia; Stradella, Agostina; Moreno-Cabrera, José Marcos; Diez Gibert, Orland; Balmaña Gelpí, Judith (MDPI, 2021-01-23)

Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study

de Wit, R.; Wülfing, C.; Castellano, D.; Kramer, G.; Eymard, J.-C.; Sternberg, C. N.; Carles Galceran, Joan (Elsevier, 2021-10)

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population

Turner, N. C.; Alarcón, E.; Armstrong, A. C.; Philco, M.; López Chuken, Y. A.; Sablin, Marie-Paule; Antunes de Melo Oliveira, Ana Mafalda (Oxford University Press, 2019-05-01)

Benefits of rIX-FP prophylaxis in patients with Haemophilia B: real-world evidence from a Spanish reference centre

Bosch Schips, Marc; Benítez Hidalgo, Olga; Juarez-Gimenez, Juan Carlos; Gironella, Mercedes (Taylor & Francis, 2023)

BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas

Moreno, Victor; Vieito Villar, Maria; Sepúlveda, Juan Manuel; Galvao De Aquiar, Vladimir; Hernández-Guerrero, T.; Doger, B.; Saavedra Gadea, Omar; Carpio Segura, Cecilia Carmen; Braña Garcia, Irene (Nature Portfolio, 2023-03-13)

Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology

Castelo-Branco, L.; Awada, Ahmad; Pentheroudakis, G.; Perez-Gracia, J. L.; Mateo Valderrama, Joaquim; Curigliano, Giuseppe; Tabernero Caturla, Josep (Elsevier, 2021-10)

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Gyawali, B.; Dafni, U.; Amaral, T.; Barriuso, J.; Bogaerts, J.; Tabernero Caturla, Josep; de Vries, Elisabeth (BMJ, 2021-06)

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort

Tan, Benjamin; Khattak, Adnan; Felip Font, Enriqueta; Kelly, Karen; Rich, Patricia; Wang, Ding (Springer, 2021-07)

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors

Barlesi, Fabrice; Isambert, Nicolas; FELIP, ENRIQUETA; Cho, Byoung Chul; Lee, Dae Ho; Peguero, Julio (Oxford University Press, 2023-03)

Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study

Yoshino, T.; Portnoy, D. C.; Obermannova, Radka; Bodoky, György; Prausová, J.; Tabernero Caturla, Josep; Garcia-Carbonero, Rocio (Oxford University Press, 2019-01-01)

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer

Matito Ariza, Judit; Antunes de Melo Oliveira, Ana Mafalda; Wildiers, Hans; Brufksy, Adam M.; Waters, Simon; Vivancos Prellezo, Ana; Saura Manich, Cristina (American Association for Cancer Research, 2021-11-01)

Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer

Ciardiello, Davide; Martin, Giulia; Famiglietti, Vincenzo; Napolitano, Stefania; Troiani, Teresa; Ros Montañá, Fco. Javier; Elez Fernandez, Mª Elena; De Falco, Vincenzo (MDPI, 2021-04-17)

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

Carreira, Suzanne; Porta, Nuria; Arce Gallego, Sara; Seed, George; Llop Guevara, Alba; Bianchini, Diletta; Serra Elizalde, Violeta; Mateo Valderrama, Joaquim (American Association for Cancer Research, 2021-05-27)

Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation

Hodkinson, Brendan P.; Schaffer, Michael; Brody, Joshua D.; Jurczak, Wojciech; Carpio Segura, Cecilia Carmen; Ben-Yehuda, Dina (Elsevier, 2021-01)

Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer

Panisello, Carla; Tirtakasuma, Ricky; Díaz-Gómez, Judit; Grases Mendoza, Daniela; Pasamar Garijo, Helena; Vivancos Prellezo, Ana; Gos, Alena; Palomero, Jara; Lozano Rabella, Maria (BMJ, 2022-12)

Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc

Massó Vallés, Daniel; Soucek, Laura (MDPI, 2020-04-04)

BRAF activation by metabolic stress promotes glycolysis sensitizing NRASQ61-mutated melanomas to targeted therapy

McGrail Fernández, Kimberley Anne; Granado Martinez, Paula; Esteve Puig, Rosaura; Garcia Ortega, Sara; Ding, Yuxin; Sanchez-Redondo Campos, Sara; Ferrer Fábrega, Berta; Hernandez Losa, Javier; Canals Suris, Francesc; Pérez, Mileidys; García-Patos Briones, Vicente; Recio Conde, Juan Angel; Muñoz Couselo, Eva (Nature Portfolio, 2022-11-19)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Browsing VHIO - Articles científics by Title

B Cells in Breast Cancer Pathology

B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

Back-to-back discovery, co-precision, and prevention

BARD1 Pathogenic Variants Are Associated with Triple-Negative Breast Cancer in a Spanish Hereditary Breast and Ovarian Cancer Cohort

Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population

Benefits of rIX-FP prophylaxis in patients with Haemophilia B: real-world evidence from a Spanish reference centre

BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas

Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors

Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer

Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation

Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer

Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc

BRAF activation by metabolic stress promotes glycolysis sensitizing NRASQ61-mutated melanomas to targeted therapy

Know Scientia

Guides and help

Go to...

Know Scientia

Guides and help

Go to...

Browsing VHIO - Articles científics by Title

B Cells in Breast Cancer Pathology ﻿

B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA) ﻿

Back-to-back discovery, co-precision, and prevention ﻿

BARD1 Pathogenic Variants Are Associated with Triple-Negative Breast Cancer in a Spanish Hereditary Breast and Ovarian Cancer Cohort ﻿

Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study ﻿

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population ﻿

Benefits of rIX-FP prophylaxis in patients with Haemophilia B: real-world evidence from a Spanish reference centre ﻿

BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas ﻿

Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology ﻿

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring ﻿

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort ﻿

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors ﻿

Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study ﻿

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer ﻿

Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer ﻿

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial ﻿

Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation ﻿

Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer ﻿

Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc ﻿

BRAF activation by metabolic stress promotes glycolysis sensitizing NRASQ61-mutated melanomas to targeted therapy ﻿

Know Scientia

Guides and help

Go to...

Know Scientia

Guides and help

Go to...

B Cells in Breast Cancer Pathology

B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

Back-to-back discovery, co-precision, and prevention

BARD1 Pathogenic Variants Are Associated with Triple-Negative Breast Cancer in a Spanish Hereditary Breast and Ovarian Cancer Cohort

Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population

Benefits of rIX-FP prophylaxis in patients with Haemophilia B: real-world evidence from a Spanish reference centre

BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas

Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors

Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer

Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation

Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer

Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc

BRAF activation by metabolic stress promotes glycolysis sensitizing NRASQ61-mutated melanomas to targeted therapy